(Z)-1,3-二氯-2-丁烯 | 10075-38-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 中文名称: (Z)-1,3-二氯-2-丁烯
• 英文名称: 1,3-Dichloro-2-butene
• 英文别名: (Z)-1,3-dichlorobut-2-ene
• CAS: 10075-38-4
• 化学式: C₄H₆Cl₂
• 分子量: 124.998
• InChiKey: WLIADPFXSACYLS-RQOWECAXSA-N

物化性质

• 熔点：
  -27.02°C (estimate)
• 沸点：
  130.15°C
• 密度：
  1.1605
• 物理描述：
  COLOURLESS-TO-YELLOW LIQUID WITH CHARACTERISTIC ODOUR.
• 颜色/状态：
  CLEAR TO STRAW-COLORED LIQUID
• 闪点：
  27 °C c.c.
• 溶解度：
  INSOL IN WATER; SOL IN MOST COMMON ORGANIC SOLVENTS
• 蒸汽密度：
  4.31 (Air = 1)
• 蒸汽压力：
  Vapor pressure, kPa at 25 °C: 1.33
• 分解：
  When heated to decomposition it emits toxic vapros of /hydrogen chloride/.
• 折光率：
  Index of refraction: 1.4692 @ 20 °C/D
• 保留指数：
  812.6

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

ADMET

毒理性

• 暴露途径

该物质可以通过吸入其蒸汽、透过皮肤和摄入的方式被身体吸收，达到危险的数量。所有暴露途径都会产生严重的局部影响。

The substance can be absorbed into the body in hazardous amounts by inhalation of its vapour, through the skin and by ingestion. Serious local effects by all routes of exposure.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 吸入症状

咳嗽。喉咙痛。

Cough. Sore throat.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 皮肤症状

红肿。疼痛。皮肤烧伤。

Redness. Pain. Skin burns.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 眼睛症状

红斑。疼痛。

Redness. Pain.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 摄入症状

咳嗽。喉咙和胸部有灼热感。

Cough. Burning sensation in the throat and chest.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

反应信息

• 作为反应物：
  描述：

  (Z)-1,3-二氯-2-丁烯 在 氯 作用下， 生成 三氯丁烯
  参考文献：
  名称：

  Carothers; Berchet, Journal of the American Chemical Society, 1933, vol. 55, p. 1629

  摘要：

  DOI：
• 作为产物：
  描述：

  1-氯-2-丁炔 在 盐酸 、 mercury dichloride 作用下， 以 溶剂黄146 为溶剂， 生成 (Z)-1,3-二氯-2-丁烯
  参考文献：
  名称：

  Gelin,R.; Pigasse,D., Bulletin de la Societe Chimique de France, 1971, p. 1840 - 1847

  摘要：

  DOI：

文献信息

• [EN] PYRAZOLE COMPOUNDS AND USE THEREOF IN NOXIOUS ARTHROPOD PESTS CONTROLLING COMPOSITION<br/>[FR] COMPOSES DERIVES DU PYRAZOLE ET LEUR UTILISATION DANS UNE COMPOSITION DE LUTTE CONTRE LES ARTHROPODES NUISIBLES
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2005075433A1

  公开（公告）日：2005-08-18

  The present invention provides a pyrazole compound of formula (a): ;a noxious arthropod pests controlling composition containing the compound shown by the formula (a) as an active ingredient; and a method for controlling noxious arthropod pests comprising applying an effective amount of the compound shown by the formula (a).

  本发明提供了一种式（a）的吡唑化合物；一种含有所述式（a）化合物作为活性成分的有害节肢动物害虫控制组合物；以及一种控制有害节肢动物害虫的方法，包括施用所述式（a）化合物的有效量。
• MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：GAVARDINAS Konstantinos

  公开号：US20090163472A1

  公开（公告）日：2009-06-25

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式(I)化合物： 或其药学上可接受的盐；包含式(I)化合物与适宜载体、稀释剂或赋形剂的药物组合物；以及治疗生理障碍，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括给予式(I)化合物或其药学上可接受的盐。
• Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
  申请人：Butora Gabor

  公开号：US20080081803A1

  公开（公告）日：2008-04-03

  The present invention is directed to compounds of the formula I: Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及以下式I的化合物： 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X、n和虚线如本文所定义，这些化合物可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。
• 7-Oxoprostacyclin derivatives and their use as hypotensives and
  申请人：Schering Aktiengesellschaft

  公开号：US04466969A1

  公开（公告）日：1984-08-21

  Prostacyclin, although having a useful dilating effect on blood vessels, is not sufficiently stable to ensure successful use as a hypotensive agent. A 7-oxo prostacyclin derivative of the general formula ##STR1## in which R.sub.1 represents the radical OR.sub.3 wherein R.sub.3 represents hydrogen, a straight-chain or branched optionally substituted, (C.sub.1 -C.sub.10)alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocyclic, or R.sub.1 represents the radical NHR.sub.4 wherein R.sub.4 represents hydrogen, or a group derived from an unsaturated or saturated, unsubstituted or substituted, (C.sub.1 -C.sub.15)organic carboxylic or sulphonic acid, A represents --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH-- or trans--CH.dbd.CH--, W represents ##STR2## either having a free or functionally modified hydroxy group which may be in the .alpha.- or .beta.-position, D and E together represent a direct bond, or D represents a straight-chain or branched, unsaturated or saturated, optionally substituted (C.sub.1 -C.sub.10)alkylene, and E represents oxygen or a direct bond, R.sub.2 represents a straight-chain or branched optionally substituted, (C.sub.1 -C.sub.10)alkyl, a straight-chain or branched optionally substituted, (C.sub.2 -C.sub.10)alkenyl, or, where D and E together represent a direct bond, a straight-chain or branched optionally substituted (C.sub.2 -C.sub.6)alkynyl, and R.sub.5 represents a free or functionally modified hydroxy group, has proved to have not only a hypotensive and bronchodilative action, for example, but also an increased stability over prostacyclin. Advantages in medicinal use over other prostaglandins have also been found.

  前列环素虽然对血管具有有益的扩张作用，但其稳定性不足以确保作为降压剂的成功应用。一种具有通式##STR1##的7-氧代前列环素衍生物，其中R1代表基团OR3，其中R3代表氢、直链或支链的可选取代的（C1-C10）烷基、可选取代的芳基、可选取代的环烷基、可选取代的杂环，或者R1代表基团NHR4，其中R4代表氢，或来自不饱和或饱和、未取代或取代的（C1-C15）有机羧酸或磺酸的基团，A代表--CH2--CH2--、顺式--CH═CH--或反式--CH═CH--，W代表##STR2##，具有自由或功能性修饰的羟基，该羟基可能位于α-或β-位置，D和E一起代表直接键，或者D代表直链或支链的、不饱和或饱和的、可选取代的（C1-C10）亚烷基，E代表氧或直接键，R2代表直链或支链的可选取代的（C1-C10）烷基、直链或支链的可选取代的（C2-C10）烯基，或者当D和E一起代表直接键时，代表直链或支链的可选取代的（C2-C6）炔基，R5代表自由或功能性修饰的羟基，已被证明不仅具有降压和支气管扩张作用，例如，而且相对于前列环素具有增加的稳定性。在药物使用方面，与其他前列腺素相比也发现了优势。
• [EN] TOTAL SYNTHESIS OF ARTEMISININ<br/>[FR] SYNTHÈSE TOTALE D'ARTÉMISININE
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2012154906A1

  公开（公告）日：2012-11-15

  The present invention provides a method for manufacturing artemisinin and its congeners from cyclohexenone as a starting material.

  本发明提供了一种从环己烯酮作为起始物质制造青蒿素及其同系物的方法。

表征谱图